Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.
Aspira Women's Health Inc'in temel mali tabloları nelerdir?
Son mali tabloya (Form-10K) göre, Aspira Women's Health Inc'in toplam varlıkları $5 olup, net 損失 $-13'dir.
AWHL'ün temel finansal oranları nelerdir?
Aspira Women's Health Inc'in cari oranı 0.62, net kâr marjı -144.44, hisse başına satış $0.63'dir.
Aspira Women's Health Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?
Aspira Women's Health Inc 最大收入來源為 Bio-analytic and Diagnostic Services,在最近的收益報告中收入為 9,154,000。就地區而言,United States 是 Aspira Women's Health Inc 的主要市場,收入為 9,154,000。
Aspira Women's Health Inc kârlı mı?
無, son mali tablolara göre Aspira Women's Health Inc'in net 損失 $-13'dir.
Aspira Women's Health Inc'in herhangi bir yükümlülüğü var mı?
是的, Aspira Women's Health Inc'in yükümlülüğü 8'dir.
Aspira Women's Health Inc'in tedavüldeki hisse sayısı kaçtır?
Aspira Women's Health Inc'in toplam tedavüldeki hisse sayısı 17.4'dir.